scispace - formally typeset
Open AccessJournal ArticleDOI

Atypical Hemolytic Uremic Syndrome

TLDR
HUS is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure that predicts the prognosis both in native kidneys and after renal transplantation.
About
This article is published in Seminars in Nephrology.The article was published on 2013-11-01 and is currently open access. It has received 258 citations till now. The article focuses on the topics: Atypical hemolytic uremic syndrome & Eculizumab.

read more

Citations
More filters
Journal ArticleDOI

Atypical hemolytic uremic syndrome

TL;DR: Case reports and two phase II trials show an impressive efficacy of the complement C5 blocker eculizumab, suggesting it will be the next standard of care.
Journal ArticleDOI

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

TL;DR: Recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options, and knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.
Journal ArticleDOI

Complement, a target for therapy in inflammatory and degenerative diseases.

TL;DR: The history, current landscape and future directions for anti-complement therapies are described, which include infectious, inflammatory, degenerative, traumatic and neoplastic disorders.
Journal ArticleDOI

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

TL;DR: Results point to efficient complement inhibition on endothelium for aHUS treatment, including C5b-9 endothelial deposits, which might help monitor eculizumab effectiveness, avoid drug overexposure, and save money considering the extremely high cost of the drug.
References
More filters
Journal ArticleDOI

Atypical Hemolytic Uremic Syndrome Associated With Complement Factor H Autoantibodies and CFHR1/CFHR3 Deficiency

TL;DR: Screening for CFH-Ab and the CFHR1/CFHR3 deficiency should be included in the diagnostic tests for patients with aHUS, and this disease may need intensive immunosuppressive therapy in addition to plasmapheresis.
Journal ArticleDOI

Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

TL;DR: In this review, the available literature on treatment strategies to date for atypical haemolytic uraemic syndrome is discussed and the introduction of the complement inhibitor Eculizumab has revolutionised the management of aHUS.
Journal ArticleDOI

Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor

TL;DR: The authors report on 2 families, in each of which a family member initially presented with sporadic HUS and subsequently received a live-related renal transplant, one from a sibling and the other from the father, which suggests that the donors may be at risk of disease recurrence.
Journal ArticleDOI

De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection.

TL;DR: The de novo occurrence of HUS immediately after the onset of primary cytomegalovirus (CMV) disease in two renal allograft recipients is described and there may be a pathophysiological link between both diseases.
Journal ArticleDOI

Attempted treatment of factor H deficiency by liver transplantation.

TL;DR: In conclusion, although APOLT showed clinical and laboratory improvement for some period in this patient, the final fatal outcome suggests that liver transplantation should be cautiously applied to patients with HUS associated with FH deficiency.
Related Papers (5)